Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy

Exclusion Criteria

• •1. Pathological histology confirmed the diagnosis of small cell lung cancer pathological type;
• •2. Treatment with prior systemic chemotherapy at any time
• •3. Confirmed EGFR or ALK mutations
• •4. Patient has a history of active autoimmune disease or autoimmune disease that may recur
• •5. Active hepatitis B and C patients will need to be on relevant antiviral therapy, have HBV-DNA \<2000 IU/ml (\<104 copies/ml) and have received anti-HBV therapy for at least 14 days prior to study participation, and continue therapy for the duration of the treatment period; HCV RNA-positive patients must be on antiviral therapy and have a liver function that is within the elevated CTCAE grade 1;
• •6. Known allergy to chemotherapy drugs including cisplatin, paclitaxel, albumin-paclitaxel and pemetrexed;
• •7. History of allergy to monoclonal antibody drugs
• •8. Patients with previous allogeneic stem cell or parenchymal organ transplantation
• •9. Having a mental illness or any other condition that renders treatment non-compliant
• •10. Patients unable or unwilling to sign the informed consent form
• •11. The investigator considered that the patient's condition may affect compliance with the protocol or make participation in this study unsuitable.